These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. Rao S Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413 [TBL] [Abstract][Full Text] [Related]
3. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914 [No Abstract] [Full Text] [Related]
4. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients. Nakagawa Y; Kuwahara K J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780 [TBL] [Abstract][Full Text] [Related]
5. Roles for SGLT2 Inhibitors in Cardiorenal Disease. Green JB; McCullough PA Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083 [TBL] [Abstract][Full Text] [Related]
6. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure. Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326 [TBL] [Abstract][Full Text] [Related]
7. Growing role of SGLT2i in heart failure: evidence from clinical trials. Varadhan A; Stephan K; Gupta R; Vyas AV; Ranchal P; Aronow WS; Hawwa N; Lanier GM Expert Rev Clin Pharmacol; 2022 Feb; 15(2):147-159. PubMed ID: 35264076 [TBL] [Abstract][Full Text] [Related]
8. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500 [TBL] [Abstract][Full Text] [Related]
9. SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR? Raschi E; Fadini GP; Diemberger I; Poluzzi E; De Ponti F Expert Opin Pharmacother; 2021 Apr; 22(5):647-650. PubMed ID: 33141609 [No Abstract] [Full Text] [Related]
10. Systematic Review of the Economic Evaluation of Sodium-Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure. Nam K; Cho DS; Kim H; Kwon B; Yoon Y; Park C; Kim ES; Youn JC; Park SK Clin Drug Investig; 2023 Jul; 43(7):463-474. PubMed ID: 37365452 [TBL] [Abstract][Full Text] [Related]
11. Sotagliflozin: Efficacy, Safety, and Potential Therapeutic Applications in Heart Failure. Long A; Salvo M Ann Pharmacother; 2024 Sep; 58(9):935-946. PubMed ID: 38014844 [TBL] [Abstract][Full Text] [Related]
12. SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled? Pabel S; Hamdani N; Luedde M; Sossalla S Curr Heart Fail Rep; 2021 Oct; 18(5):315-328. PubMed ID: 34523061 [TBL] [Abstract][Full Text] [Related]
13. SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis. Banerjee M; Pal R; Nair K; Mukhopadhyay S Indian Heart J; 2023; 75(2):122-127. PubMed ID: 36914068 [TBL] [Abstract][Full Text] [Related]
14. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction. De Lorenzi AB; Kaplinsky E; Zambrano MR; Chaume LT; Rosas JM Drugs Context; 2023; 12():. PubMed ID: 36660013 [TBL] [Abstract][Full Text] [Related]
15. Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review. Jhalani NB Adv Ther; 2022 Aug; 39(8):3472-3487. PubMed ID: 35699903 [TBL] [Abstract][Full Text] [Related]
16. Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction. Abdelhamid M; Kandil H; Hassanin M; Shaheen S; Sobhy M; ElEtreby A; Hasan-Ali H; Mahfouz H; Nasr G; Shawky I; Emil S; ElSetiha M; Hasssan M; Sadek Y; Karim MA; Asham A; Ghaleb M; Samir A; Shokry K ESC Heart Fail; 2022 Apr; 9(2):800-811. PubMed ID: 35118822 [TBL] [Abstract][Full Text] [Related]
17. SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms. Nikolic M; Zivkovic V; Jovic JJ; Sretenovic J; Davidovic G; Simovic S; Djokovic D; Muric N; Bolevich S; Jakovljevic V Heart Fail Rev; 2022 May; 27(3):935-949. PubMed ID: 33534040 [TBL] [Abstract][Full Text] [Related]